Inventiva S.A. released preliminary unaudited financial results for the year ended December 31, 2025, showing cash and cash equivalents of €99.3 million and short‑term deposits of €131.6 million, up from €96.6 million and €131.6 million at the end of 2024. The increase reflects the company’s recent structured financing and public offering that bolstered liquidity.
Revenue fell to €4.5 million in 2025, a 51% decline from €9.2 million in 2024. The drop is largely attributable to the absence of a second milestone payment from Chia Tai Tianqing Pharmaceutical Group (CTTQ) that was received in 2024. In 2025, Inventiva received a €10 million milestone payment and €5 million in credit notes from CTTQ in July, but no additional milestone was paid, leaving revenue lower.
Operating cash burn increased by 22% year‑over‑year to €12.3 million, driven by a pipeline prioritization plan that shifted resources toward late‑stage development of lanifibranor, higher general and administrative expenses, and a modest rise in research and development costs. The company’s management emphasized that the higher burn is a deliberate investment to accelerate the Phase 3 NATiV3 trial.
Despite the revenue decline, Inventiva’s cash runway extends through mid‑Q1 2027, with the possibility of reaching mid‑Q3 2027 if warrants are exercised. The strengthened liquidity positions the company to sustain its clinical program and to pursue additional financing if needed.
Management noted that the company’s focus on lanifibranor, a dual PPAR agonist for metabolic dysfunction‑associated steatohepatitis, remains unchanged. The company continues to monitor the evolving MASH market, which is projected to exceed $15 billion by 2035, and is preparing for potential regulatory submissions in 2026.
Analysts remain cautiously optimistic, citing the company’s robust cash position and the strategic focus on a high‑potential therapeutic area, while noting that the lack of recurring milestone revenue underscores the need for future licensing or partnership deals to support long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.